Current UK guidance advises that Lomexin should be avoided in pregnancy unless a prescriber determines that the potential benefit outweighs the risk. Limited safety data exist for the first trimester, so a healthcare professional will assess alternative treatments.
Women often notice a reduction in itching and discharge within 48 hours of insertion, although complete resolution may take up to a week, depending on infection severity.
A single dose is the standard regimen for uncomplicated infections, but clinicians may prescribe a repeat dose after a few days for more persistent cases. The exact schedule should be individualized.
Fenticonazole, like other azoles, can increase plasma concentrations of estrogen-containing contraceptives. Using a backup non-hormonal method (e.g., condoms) during treatment is recommended.
Mild local irritation is common. If discomfort persists beyond 24 hours, becomes severe, or is accompanied by swelling or ulceration, seek medical evaluation.
No dietary restrictions are required because the medication is administered vaginally and does not interact with food.
Lomexin is formulated for vaginal administration only. Other azole preparations (e.g., oral fluconazole) are appropriate for systemic or non-vaginal fungal infections.
The medication treats the current infection but does not provide lasting prophylaxis. Maintaining good vaginal hygiene and managing predisposing factors (e.g., diabetes control) reduces recurrence risk.
Keep the suppositories at room temperature, away from moisture, and in their original packaging. If traveling to a hot climate, avoid leaving the product in a vehicle or exposed to direct sunlight.
Repeated or inappropriate use of any antifungal can promote resistant Candida strains. Use Lomexin exactly as prescribed and complete the full course to minimise this risk.
Lomexin is a vaginal suppository that contains fenticonazole as its sole active component. Fenticonazole belongs to the azole class of antifungal agents and is used primarily in women’s health to treat fungal infections of the vagina and surrounding tissues. In the United Kingdom, Lomexin is classified as a prescription-only medicine (POM) and is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The product is supplied as a 600 mg suppository, designed for insertion into the vagina where it releases the active ingredient locally.
Fenticonazole exerts its antifungal effect by inhibiting the enzyme lanosterol 14α-demethylase, an essential step in the synthesis of ergosterol, the principal sterol component of fungal cell membranes. By blocking ergosterol production, the drug disrupts membrane integrity, leading to increased permeability, leakage of cellular contents, and ultimately fungal cell death.
Key pharmacologic points:
Lomexin is approved in the UK for the treatment of uncomplicated vulvovaginal candidiasis (VVC) and other superficial fungal infections of the vagina. These conditions are characterized by itching, discharge, and irritation caused by overgrowth of Candida species.
Typical patient profile:
Note: Patients should disclose all prescription, over-the-counter, herbal, and supplement use to their healthcare provider before starting Lomexin.
This article provides educational information about Lomexin and is not a substitute for professional medical advice. Treatment decisions, including the use of Lomexin for any condition, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
